NT5E (dresbuxelimab Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA723415MB1HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:NT5E (dresbuxelimab Biosimilar Antibody) 重組單克隆抗體是一種針對5'核苷酸酶(CD73),其別名包括5' NT抗體、CD73抗體、Ecto-5'-核苷酸酶抗體等。該抗體以重組人NT5E蛋白制備,具有高度的種屬反應(yīng)性,主要針對人類NT5E蛋白發(fā)揮特異性結(jié)合作用。 dresbuxelimab Biosimilar Antibody的開發(fā)聚焦于腫瘤免疫治療。CD73作為一種細胞表面酶,通過將細胞外腺苷一磷酸(AMP)轉(zhuǎn)化為腺苷,在腫瘤微環(huán)境中誘導(dǎo)免疫抑制,促進腫瘤細胞的免疫逃逸。臨床前研究表明,該抗體研發(fā)的藥物可有效阻斷CD73的酶活性,減少腺苷生成,從而解除免疫抑制,增強T細胞介導(dǎo)的抗腫瘤免疫應(yīng)答。目前,相關(guān)臨床試驗正探索其單藥或聯(lián)合PD-1/PD-L1抑制劑在實體瘤(如結(jié)直腸癌、三陰性乳腺癌)中的療效與安全性,初步結(jié)果顯示其具有良好的耐受性和潛在的抗腫瘤活性。 NT5E抗體廣泛應(yīng)用于分子生物學和細胞生物學研究。研究者可利用其特異性結(jié)合特性,通過技術(shù)檢測NT5E在正常組織和腫瘤樣本中的表達水平,分析其與腫瘤分期、預(yù)后的相關(guān)性。此外,該抗體還可用于體外細胞模型中CD73功能的調(diào)控研究,助力闡明NT5E在腫瘤微環(huán)境重塑、血管生成及免疫調(diào)節(jié)中的分子機制,為開發(fā)新型靶向治療策略提供實驗基礎(chǔ)。其高度的種屬特異性和親和力,使其成為研究人類NT5E生物學功能的重要工具。
-
Uniprot No.:
-
基因名:
-
別名:5' NT antibody; 5' nucleotidase;CD73 antibody; 5' nucleotidase precursor antibody; 5' nucleotidase; ecto antibody; 5' nucleotidase; ecto;CD73 antibody; 5'-NT antibody; 5'-nucleotidase antibody; 5NTD_HUMAN antibody; CD73 antibody; CD73 antigen antibody; E5NT antibody; Ecto 5' nucleotidase antibody; Ecto-5'-nucleotidase antibody; eN antibody; eNT antibody; NT antibody; NT5 antibody; NT5E antibody; NTE antibody; Purine 5 Prime Nucleotidase antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human NT5E protein
-
免疫原種屬:Homo sapiens (Human)
-
標記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:In stock
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
-
基因功能參考文獻:
- Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
- High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
- Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
- High CD73 expression is associated with breast cancer. PMID: 29047106
- High CD73 expression is associated with neoplasms. PMID: 29514610
- NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
- soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
- High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
- analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
- The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
- this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
- high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
- Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
- we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
- Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
- Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
- Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
- HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
- High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
- Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
- High CD73 expression is associated with cervical cancer. PMID: 28202050
- Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
- Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
- CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
- CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
- This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
- concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
- Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
- Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
- CD73 may play an important role in breast cancer stem cells. PMID: 27670764
- This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
- Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
- These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
- CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
- Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
- The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
- CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
- report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
- findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
- CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
- these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
- This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
- role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
- Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
- Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
- rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
- Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
- The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
- CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
- It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814
顯示更多
收起更多
-
相關(guān)疾病:Calcification of joints and arteries (CALJA)
-
亞細胞定位:Cell membrane; Lipid-anchor, GPI-anchor.
-
蛋白家族:5'-nucleotidase family
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















